Skip to main content
Journal cover image

Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma.

Publication ,  Journal Article
Farrow, NE; Holl, EK; Jung, J; Gao, J; Jung, S-H; Al-Rohil, RN; Selim, MA; Mosca, PJ; Ollila, DW; Antonia, SJ; Tyler, DS; Nair, SK; Beasley, GM
Published in: Ann Surg Oncol
July 2021

BACKGROUND: Although sentinel lymph node (SLN) biopsy is a standard procedure used to identify patients at risk for melanoma recurrence, it fails to risk-stratify certain patients accurately. Because processes in SLNs regulate anti-tumor immune responses, the authors hypothesized that SLN gene expression may be used for risk stratification. METHODS: The Nanostring nCounter PanCancer Immune Profiling Panel was used to quantify expression of 730 immune-related genes in 60 SLN specimens (31 positive [pSLNs], 29 negative [nSLNs]) from a retrospective melanoma cohort. A multivariate prediction model for recurrence-free survival (RFS) was created by applying stepwise variable selection to Cox regression models. Risk scores calculated on the basis of the model were used to stratify patients into low- and high-risk groups. The predictive power of the model was assessed using the Kaplan-Meier and log-rank tests. RESULTS: During a median follow-up period of 6.3 years, 20 patients (33.3%) experienced recurrence (pSLN, 45.2% [14/31] vs nSLN, 20.7% [6/29]; p = 0.0445). A fitted Cox regression model incorporating 12 genes accurately predicted RFS (C-index, 0.9919). Improved RFS was associated with increased expression of TIGIT (p = 0.0326), an immune checkpoint, and decreased expression of CXCL16 (p = 0.0273), a cytokine important in promoting dendritic and T cell interactions. Independent of SLN status, the model in this study was able to stratify patients into cohorts at high and low risk for recurrence (p < 0.001, log-rank). CONCLUSIONS: Expression profiles of the SLN gene are associated with melanoma recurrence and may be able to identify patients as high or low risk regardless of SLN status, potentially enhancing patient selection for adjuvant therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

July 2021

Volume

28

Issue

7

Start / End Page

3501 / 3510

Location

United States

Related Subject Headings

  • Skin Neoplasms
  • Sentinel Lymph Node Biopsy
  • Sentinel Lymph Node
  • Risk Assessment
  • Retrospective Studies
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Melanoma
  • Lymphatic Metastasis
  • Lymph Nodes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Farrow, N. E., Holl, E. K., Jung, J., Gao, J., Jung, S.-H., Al-Rohil, R. N., … Beasley, G. M. (2021). Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma. Ann Surg Oncol, 28(7), 3501–3510. https://doi.org/10.1245/s10434-020-09277-w
Farrow, Norma E., Eda K. Holl, Jeanne Jung, Junheng Gao, Sin-Ho Jung, Rami N. Al-Rohil, Maria A. Selim, et al. “Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma.Ann Surg Oncol 28, no. 7 (July 2021): 3501–10. https://doi.org/10.1245/s10434-020-09277-w.
Farrow NE, Holl EK, Jung J, Gao J, Jung S-H, Al-Rohil RN, et al. Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma. Ann Surg Oncol. 2021 Jul;28(7):3501–10.
Farrow, Norma E., et al. “Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma.Ann Surg Oncol, vol. 28, no. 7, July 2021, pp. 3501–10. Pubmed, doi:10.1245/s10434-020-09277-w.
Farrow NE, Holl EK, Jung J, Gao J, Jung S-H, Al-Rohil RN, Selim MA, Mosca PJ, Ollila DW, Antonia SJ, Tyler DS, Nair SK, Beasley GM. Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma. Ann Surg Oncol. 2021 Jul;28(7):3501–3510.
Journal cover image

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

July 2021

Volume

28

Issue

7

Start / End Page

3501 / 3510

Location

United States

Related Subject Headings

  • Skin Neoplasms
  • Sentinel Lymph Node Biopsy
  • Sentinel Lymph Node
  • Risk Assessment
  • Retrospective Studies
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Melanoma
  • Lymphatic Metastasis
  • Lymph Nodes